New test for thyroid cancer could prevent unnecessary surgery

October 07, 2019

Researchers at The University of Texas at Austin and Baylor College of Medicine have developed a new preoperative test for thyroid cancer that is faster and about two-thirds more accurate than the diagnostic tests doctors use today. Although more validation will be necessary before it can be used clinically, the new metabolic thyroid test shows promise for preventing thousands of unnecessary thyroid removals each year, such as the partial removal UT Austin grad student Amanda Helms had due to an inconclusive test.

"All the uncertainty was nerve wracking," Helms said.

The results appear this week (starting Oct. 7) in the journal Proceedings of the National Academy of Sciences.

"If we could prevent people from having surgery they don't need and enable them to have a more precise diagnosis, we can improve treatment for patients and lower costs for the health care system," said Livia S. Eberlin, assistant professor of chemistry and diagnostic medicine at The University of Texas at Austin and co-principal investigator.

Rachel DeHoog, a graduate student who worked on the study, added, "Also very importantly, the ability to have certainty in your diagnosis is transformative for a patient presented with the grueling possibility of having cancer."

Each year in the U.S., about 52,000 new cases of thyroid cancer are diagnosed. Unfortunately, the test used for diagnosis, called fine needle aspiration (FNA), is inconclusive about 1 out of every 5 times. When a pathologist is unable to confirm the presence of cancer, the patient may receive a follow-up genetic test that itself can produce false positive results.

Given the uncertainties, doctors often recommend removing part or all of the thyroid - the gland in the neck producing hormones that control the body's metabolic rate, as well as heart and digestive function, muscle control, brain development, mood and bone maintenance. Thousands of patients each year have the surgery only to later learn it was unnecessary.

Using a technology called mass spectrometry imaging, the new metabolic thyroid test identifies metabolites produced by cancerous cells that act as a kind of diagnostic fingerprint. The researchers worked on identifying these diagnostic metabolic fingerprints for over two years using 178 patient tissues before starting a pilot clinical study. During the clinical study, 68 new patients were tested, nearly a third of whom had received inconclusive FNA results. The new metabolic thyroid test returned a false positive only about 1 time in 10 and could have prevented 17 patients in the study from undergoing unnecessary surgeries.

The improved accuracy would prevent unnecessary surgeries, many of which lead patients to need hormone replacement therapy for the rest of their lives or to have to cope with other consequences of having all or part of their thyroid removed. For example, Helms, a graduate student in chemistry at UT Austin, learned a few years ago as an undergraduate student at the age of 19 that lumps on her thyroid were indicative of possible cancer. When her FNA biopsy came back as inconclusive, a doctor recommended removing the right half of her thyroid. For Helms, a difficult surgery and recovery followed, though she soon received word that pathologists detected no cancer in the removed tissue. Helms says the new test could prevent others from going through what she did.

"A lot fewer people would have to get surgery unnecessarily, which saves them time, money and recovery," Helms said. "It would also take away the uncertainty."

James Suliburk, a co-principal investigator and head of endocrine surgery at Baylor College of Medicine in Houston, collected FNA biopsies from the patients involved in the study and implemented the technology in a pilot trial to demonstrate the accuracy of the new test.

"With this next generation test, we can provide thyroid cancer diagnoses faster and with more precision than current techniques - this will be the new state-of-the-art," said Suliburk, who operates at Baylor St. Luke's Medical Center and Harris Health System's Ben Taub Hospital. "We are able to do this analysis directly on the FNA sample and much more rapidly than the current process, which could take between three and 30 days."

The team is now preparing to start a two-year validation study on FNAs from about a thousand new patients collected in the U.S., Brazil and Australia. If the results hold up, they hope the technology will be translated to the clinic as a routine diagnostic tool.
-end-
The study's other co-authors are Rachel DeHoog, Jialing Zhang, John Lin, Christopher Almendariz, Monica Lin and Spencer Woody at UT Austin; Elizabeth Alore and Wendong Yu at Baylor; Anton Engelsman and Stan Sidhu at the University of Sydney in Australia; and Robert Tibshirani at Stanford University, who is also a co-principal investigator.

Eberlin, Suliburk, Yu, Zhang, DeHoog and Alore are inventors on a provisional patent application owned by the Board of Regents of the University of Texas System and Baylor College of Medicine that relates to the use of mass spectrometry to diagnose thyroid cancer.

This study was funded by the Cancer Prevention & Research Institute of Texas (CPRIT) through an Early Translation Research Award to Eberlin and Suliburk.

University of Texas at Austin

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.